FDA: One Patient’s Unique Experience Misleads on Efficacy in Novartis Aid
Novartis’ use of case studies in cancer drug Gleevec’s advertising material is misleading because one patient’s experience does not count as substantial evidence, the FDA says.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.